Candriam Luxembourg S.C.A. Sells 5,000 Shares of Vanda Pharmaceuticals Inc. (NASDAQ:VNDA)

Candriam Luxembourg S.C.A. cut its holdings in Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) by 1.8% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 266,000 shares of the biopharmaceutical company’s stock after selling 5,000 shares during the quarter. Candriam Luxembourg S.C.A. owned approximately 0.50% of Vanda Pharmaceuticals worth $4,365,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds and other institutional investors have also bought and sold shares of the company. Rhumbline Advisers grew its position in shares of Vanda Pharmaceuticals by 5.4% during the 4th quarter. Rhumbline Advisers now owns 172,367 shares of the biopharmaceutical company’s stock valued at $2,829,000 after acquiring an additional 8,770 shares during the period. Principal Financial Group Inc. grew its position in shares of Vanda Pharmaceuticals by 2.1% during the 4th quarter. Principal Financial Group Inc. now owns 429,168 shares of the biopharmaceutical company’s stock valued at $7,043,000 after acquiring an additional 8,980 shares during the period. Aigen Investment Management LP bought a new stake in shares of Vanda Pharmaceuticals during the 4th quarter valued at $866,000. Emerald Mutual Fund Advisers Trust bought a new stake in shares of Vanda Pharmaceuticals during the 4th quarter valued at $4,131,000. Finally, Emerald Advisers LLC bought a new stake in shares of Vanda Pharmaceuticals during the 4th quarter valued at $4,242,000. 99.50% of the stock is currently owned by institutional investors.

A number of equities research analysts have recently issued reports on the stock. BidaskClub downgraded shares of Vanda Pharmaceuticals from a “sell” rating to a “strong sell” rating in a research report on Saturday, February 1st. Citigroup downgraded shares of Vanda Pharmaceuticals from a “buy” rating to a “neutral” rating and set a $19.00 price objective for the company. in a research report on Thursday, November 7th. Stifel Nicolaus reissued a “hold” rating on shares of Vanda Pharmaceuticals in a research report on Sunday, February 2nd. ValuEngine raised shares of Vanda Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Friday, January 3rd. Finally, Zacks Investment Research downgraded shares of Vanda Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Saturday, February 8th. One investment analyst has rated the stock with a sell rating and five have issued a hold rating to the company. Vanda Pharmaceuticals has an average rating of “Hold” and a consensus target price of $17.75.

Shares of VNDA stock opened at $12.70 on Friday. Vanda Pharmaceuticals Inc. has a 1 year low of $11.83 and a 1 year high of $21.41. The firm has a fifty day moving average price of $14.75 and a 200-day moving average price of $14.73. The company has a market cap of $677.38 million, a price-to-earnings ratio of 5.70 and a beta of 0.27.

In related news, CEO Mihael Hristos Polymeropoulos sold 9,467 shares of the company’s stock in a transaction on Thursday, January 2nd. The shares were sold at an average price of $16.00, for a total value of $151,472.00. Following the completion of the transaction, the chief executive officer now owns 1,234,579 shares of the company’s stock, valued at approximately $19,753,264. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, CFO James Patrick Kelly sold 4,020 shares of the company’s stock in a transaction on Thursday, January 2nd. The stock was sold at an average price of $15.94, for a total transaction of $64,078.80. Following the completion of the transaction, the chief financial officer now directly owns 205,726 shares of the company’s stock, valued at approximately $3,279,272.44. The disclosure for this sale can be found here. Insiders sold a total of 14,642 shares of company stock valued at $234,100 in the last ninety days. 8.20% of the stock is currently owned by insiders.

About Vanda Pharmaceuticals

Vanda Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs and improve the lives of patients. The company's marketed products include HETLIOZ (tasimelteon), a product for the treatment of non-24-hour sleep-wake disorders; and Fanapt (iloperidone), a product for the treatment of schizophrenia.

Recommended Story: What is the outlook for the FAANG stocks?

Want to see what other hedge funds are holding VNDA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Vanda Pharmaceuticals Inc. (NASDAQ:VNDA).

Institutional Ownership by Quarter for Vanda Pharmaceuticals (NASDAQ:VNDA)

Receive News & Ratings for Vanda Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vanda Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.